Ann Pediatr Endocrinol Metab.  2025 Feb;30(1):1-2. 10.6065/apem.2524129edi01.

Commentary on "Somatrogon in pediatric growth hormone deficiency: a comprehensive review of clinical trials and real-world considerations"

• Kim YM

• KMID: 2565209
• DOI: http://doi.org/10.6065/apem.2524129edi01

Reference

References

1. Hirsch IB, Juneja R, Beals JM, Antalis CJ, Wright EE. The evolution of insulin and how it informs therapy and treatment choices. Endocr Rev. 2020; 41:733–55.

2. Seo JY, Lee CG, Choi H, Lee HK, Lee SY, Kim HJ, et al. Effects of once-weekly dulaglutide on juvenile type 2 diabetes mellitus and obesity in Korea: a pilot study. Ann Pediatr Endocrinol Metab. 2023; 28:296–301.

3. Kim SJ, Kim JH, Hong YH, Chung IH, Lee EB, Kang E, et al. 2022 Clinical practice guidelines for central precocious puberty of Korean children and adolescents. Ann Pediatr Endocrinol Metab. 2023; 28:168–77.

4. Holida M, Linhart A, Pisani A, Longo N, Eyskens F, Goker-Alpan O, et al. A phase III, open-label clinical trial evaluating pegunigalsidase alfa administered every 4 weeks in adults with Fabry disease previously treated with other enzyme replacement therapies. J Inherit Metab Dis. 2025; 48:e12795.

5. Hasegawa Y, Ikegawa K, Mitani-Konno M, Ariyasu D, Amano N. Current understanding and perspectives on growth and long-acting GH therapy in Japan. Clin Pediatr Endocrinol. 2025; 34:1–12.

6. Grillo MS, Frank J, Saenger P. Long-acting growth hormone (LAGH), an update. Front Pediatr. 2023; 11:1254231.

7. Maniatis AK, Wajnrajch MP, Thomas M, Chung SB, Lee J. Somatrogon in pediatric growth hormone deficiency: a comprehensive review of clinical trials and real-world considerations. Ann Pediatr Endocrinol Metab. 2025; 30:11–6.

8. Zelinska N, Iotova V, Skorodok J, Malievsky O, Peterkova V, Samsonova L, et al. Long-acting C-terminal peptide-modified hGH (MOD-4023): results of a safety and dose-finding study in GHD children. J Clin Endocrinol Metab. 2017; 102:1578–87.

9. Deal CL, Steelman J, Vlachopapadopoulou E, Stawerska R, Silverman LA, Phillip M, et al. Efficacy and safety of weekly somatrogon vs daily somatropin in children with growth hormone deficiency: a phase 3 study. J Clin Endocrinol Metab. 2022; 107:e2717–28.

10. Horikawa R, Tanaka T, Hasegawa Y, Yorifuji T, Ng D, Rosenfeld RG, et al. Efficacy and safety of once-weekly somatrogon compared with once-daily somatropin (Genotropin(R)) in Japanese children with pediatric growth hormone deficiency: results from a randomized phase 3 study. Horm Res Paediatr. 2022; 95:275–85.

11. Zadik Z, Zelinska N, Iotova V, Skorodok Y, Malievsky O, Mauras N, et al. An open-label extension of a phase 2 dose-finding study of once-weekly somatrogon vs. once-daily Genotropin in children with short stature due to growth hormone deficiency: results following 5 years of treatment. J Pediatr Endocrinol Metab. 2023; 36:261–9.

12. Maniatis AK, Carakushansky M, Galcheva S, Prakasam G, Fox LA, Dankovcikova A, et al. Treatment burden of weekly somatrogon vs daily somatropin in children with growth hormone deficiency: a randomized study. J Endocr Soc. 2022; 6:bvac117.

13. Geffner ME, Ranke MB, Wajnrajch MP; Pfizer International Growth Database Strategic Executive Committee, Strategic Advisory Board, and International Board. An overview of growth hormone therapy in pediatric cases documented in the Kabi International Growth Study (Pfizer International Growth Database). Ann Pediatr Endocrinol Metab. 2024; 29:3–11.

14. Pfäffle R, Land C, Schönau E, Holterhus PM, Ross JL, Piras de Oliveira C, et al. Growth hormone treatment for short stature in the USA, Germany and France: 15 years of surveillance in the genetics and neuroendocrinology of short-stature international study (GeNeSIS). Horm Res Paediatr. 2018; 90:169–80.

15. Rhie YJ, Yoo JH, Choi JH, Chae HW, Kim JH, Chung S, et al. Long-term safety and effectiveness of growth hormone therapy in Korean children with growth disorders: 5-year results of LG Growth Study. PLoS One. 2019; 14:e0216927.